Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STAT3 | P40763 | 1/20 | 0.55 |
| ▸ | HSP90AA1 | P07900 | 12/20 | 0.43 |
| ▸ | HSP90AB1 | P08238 | 12/20 | 0.43 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.40 |
| ▸ | BRAF | P15056 | 2/20 | 0.36 |
| ▸ | CCR4 | P51679 | 1/20 | 0.36 |
| ▸ | PGAM1 | P18669 | 1/20 | 0.36 |
| ▸ | BCL2 | P10415 | 1/20 | 0.36 |
| ▸ | BID | P55957 | 1/20 | 0.36 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.36 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.36 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.36 |
| ▸ | BCL2A1 | Q16548 | 1/20 | 0.36 |
| ▸ | BCL2L2 | Q92843 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13509830 | 0.88 | STAT3 (0.60) | STAT3HSP90AA1HSP90AB1MCL1BRAF | |
| SCHEMBL13509836 | 0.83 | STAT3 (0.63) | STAT3HSP90AA1HSP90AB1MCL1BRAF | |
| SCHEMBL13509821 | 0.81 | STAT3 (0.60) | STAT3HSP90AA1HSP90AB1BRAFPGAM1 | |
| SCHEMBL13510485 | 0.81 | BRAF (0.56) | HSP90AA1MCL1BRAFCCR4PGAM1 | |
| SCHEMBL13509762 | 0.77 | BRAF (0.60) | STAT3MCL1BRAFBCL2BID | |
| SCHEMBL13509801 | 0.77 | HSP90AA1 (0.70) | STAT3HSP90AA1HSP90AB1MCL1BRAF | |
| SCHEMBL13509814 | 0.76 | STAT3 (0.66) | STAT3HSP90AA1HSP90AB1 | |
| SCHEMBL13509810 | 0.76 | STAT3 (0.72) | STAT3HSP90AA1HSP90AB1BRAF | |
| SCHEMBL13509850 | 0.75 | STAT3 (0.74) | STAT3HSP90AA1HSP90AB1MCL1KEAP1 | |
| SCHEMBL13509803 | 0.75 | STAT3 (0.67) | STAT3HSP90AA1HSP90AB1MCL1PGAM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11161831-B2 | Methods and compositions for treatment of muscle wasting, muscle weakness, and/or cachexia | BAYLOR COLLEGE OF MEDICINE (US) | 2021-11-02 | — | — | US | disclosed |
| WO-2021113551-A1 | THERAPEUTIC COMPOUNDS FOR METHODS OF USE IN INSULIN RESISTANCE | BAYLOR COLLEGE OF MEDICINE (US) | 2021-06-10 | — | — | WO | disclosed |
| US-20200331880-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF MUSCLE WASTING, MUSCLE WEAKNESS, AND/OR CACHEXIA | BAYLOR COLLEGE OF MEDICINE | 2020-10-22 | — | — | US | disclosed |
| US-10676455-B2 | Methods and compositions for treatment of muscle wasting, muscle weakness, and/or cachexia | BAYLOR COLLEGE OF MEDICINE (US) | 2020-06-09 | — | — | US | disclosed |
| US-20150051233-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF FIBROSIS | BAYLOR COLLEGE OF MEDICINE | 2015-02-19 | — | — | US | disclosed |
| US-20150051233-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF FIBROSIS | BAYLOR COLLEGE OF MEDICINE | 2015-02-19 | — | — | US | disclosed |
| US-20150031714-A1 | METHODS AND COMPOSITIONS FOR PREVENTION OF ALLERGIC REACTION | BAYLOR COLLEGE OF MEDICINE | 2015-01-29 | — | — | US | disclosed |
| US-20150024032-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF MUSCLE WASTING, MUSCLE WEAKNESS, AND/OR CACHEXIA | BAYLOR COLLEGE OF MEDICINE | 2015-01-22 | — | — | US | disclosed |
| US-20140296270-A1 | STAT3 Inhibitors | BAYLOR COLLEGE OF MEDICINE (US) | 2014-10-02 | — | — | US | disclosed |
| US-8779001-B2 | Stat3 inhibitors | The United States of America National Institute of Health (NIH) (US) | 2014-07-15 | — | — | US | disclosed |
| US-8779001-B2 | Stat3 inhibitors | The United States of America National Institute of Health (NIH) (US) | 2014-07-15 | — | — | US | disclosed |
| US-20110312984-A1 | STAT3 INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-12-22 | — | — | US | disclosed |
| US-20110312984-A1 | STAT3 INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-12-22 | — | — | US | disclosed |
| US-20100041685-A1 | STAT3 INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-02-18 | — | — | US | disclosed |
| US-20100041685-A1 | STAT3 INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150051233-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF FIBROSIS | STAT3, MMP1, MMP8 | STAT3 1/4885HSP90AA1 347/4885HSP90AB1 230/4885 |
| US-10676455-B2 | Methods and compositions for treatment of muscle wasting, muscle weakness, and/or cachexia | PYGM, MYLK2, STAT3 | STAT3 3/4885HSP90AA1 508/4885HSP90AB1 346/4885 |
| US-11161831-B2 | Methods and compositions for treatment of muscle wasting, muscle weakness, and/or cachexia | PYGM, MYLK2, STAT3 | STAT3 3/4885HSP90AA1 508/4885HSP90AB1 346/4885 |
| US-20150024032-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF MUSCLE WASTING, MUSCLE WEAKNESS, AND/OR CACHEXIA | PYGM, MYLK2, STAT3 | STAT3 3/4885HSP90AA1 508/4885HSP90AB1 346/4885 |
| US-20100041685-A1 | STAT3 INHIBITORS | STAT3, STAT1, JAK2 | STAT3 1/4885HSP90AA1 231/4885HSP90AB1 254/4885 |
| US-20200331880-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF MUSCLE WASTING, MUSCLE WEAKNESS, AND/OR CACHEXIA | PYGM, MYLK2, STAT3 | STAT3 3/4885HSP90AA1 508/4885HSP90AB1 346/4885 |
| US-20140296270-A1 | STAT3 Inhibitors | STAT3, STAT1, JAK2 | STAT3 1/4885HSP90AA1 231/4885HSP90AB1 254/4885 |
| US-20150031714-A1 | METHODS AND COMPOSITIONS FOR PREVENTION OF ALLERGIC REACTION | JAK2, STAT3, STAT6 | STAT3 2/4885HSP90AA1 1192/4885HSP90AB1 937/4885 |
| US-20110312984-A1 | STAT3 INHIBITORS | STAT3, STAT1, JAK2 | STAT3 1/4885HSP90AA1 231/4885HSP90AB1 254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.